Blood Preparation Market Size, Share & Trends Analysis Report By Product Type (Whole Blood, Blood Components, Blood Derivatives), By Antithrombotic and Anticoagulants Type (Platelet Aggregation Inhibitors, Fibrinolytics, Anticoagulants, Direct Thrombin Inhibitors, Vitamin K Antagonists, Direct Factor Xa Inhibitors), By Application (Thrombocytosis, Renal Impairment, Pulmonary Embolism, Angina & Blood Vessel Complications, Others), By End User (Clinics, Hospitals, Diagnostic Centers, Research Labs, Blood Banks, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Blood Preparation Market Size

The global blood preparation market size was valued at USD 50.04 billion in 2024 and is projected to grow from USD 52.96 billion in 2025 to reach USD 83.47 billion by 2033, growing at a CAGR of 5.85% during the forecast period (2025–2033).

The global blood preparation market is primarily driven by the surging prevalence of chronic diseases such as cancer, anemia, hemophilia, and cardiovascular disorders, which significantly increase the demand for blood components like plasma, platelets, and red blood cells. This trend is further supported by a growing geriatric population worldwide, as older individuals are more susceptible to chronic conditions that necessitate regular transfusions or anticoagulant therapy.

Additionally, government initiatives and awareness programs promoting blood donation and enhancing transfusion safety have also contributed to improved access to blood products and boosted public participation. Furthermore, the expanding network of blood banks and collection centers, especially in emerging economies, is enhancing the availability and management of blood supplies. Moreover, the flourishing awareness regarding the importance of early diagnosis and treatment of blood-related disorders has led to higher demand for efficient blood preparation and storage solutions. Together, these factors are fueling the growth and evolution of the global market.

Latest Market Trends

Technological innovation in pathogen reduction systems

Technological innovation in pathogen reduction systems is transforming the global blood preparation industry by significantly enhancing the safety and efficacy of blood products. These cutting-edge systems work by inactivating a wide range of pathogens—including viruses, bacteria, and parasites—thereby reducing the risk of transfusion-transmitted infections and improving patient outcomes.

• For instance, in October 2024, Cerus secured a $32.1 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to further develop the INTERCEPT Blood System for red blood cells. This system uses amustaline, a small molecule that intercalates and crosslinks nucleic acids, effectively preventing pathogen replication.

As regulatory approvals increase and healthcare providers prioritize safer transfusion methods, the adoption of such innovative pathogen reduction technologies is expected to accelerate, driving substantial growth in the market for blood preparation.

Blood Preparation Market Drivers

Increasing number of surgical procedures and trauma cases globally

The elevating number of surgical procedures and trauma cases worldwide is a significant driver for the market for blood preparation. Continuous advancements in medical technology, coupled with expanding healthcare infrastructure, have contributed to increasing surgical volumes, particularly in emerging economies. Blood components such as plasma, red blood cells, and platelets are critical for managing hemorrhages and ensuring patient survival during surgeries and trauma care.

• According to an article published in PubMed Central, around 315 million surgical procedures are performed globally each year, with projections estimating this number to reach between 430 million and 550 million by 2030.
• Additionally, the World Health Organization (WHO) reports that nearly 5 million people die annually due to traumatic injuries, while another 45 million experience life-altering injuries.

This growing patient population is expected to substantially boost demand for blood preparation products, driving market growth in the coming years.

Market Restraining Factors

Risk of contamination and transmission of infections

One of the major restraints in the global blood preparation market is the persistent risk of contamination and transmission of infections during blood collection, storage, and transfusion. Despite rigorous screening procedures, there remains a possibility of transmitting diseases like HIV, hepatitis B and C, and syphilis. This risk is particularly high in regions with inadequate healthcare infrastructure and limited access to advanced screening technologies.

Moreover, improper handling and storage of blood products can lead to bacterial contamination, compromising patient safety. These challenges not only deter patients and healthcare providers from trusting blood products but also result in increased regulatory scrutiny and operational costs for manufacturers and blood banks.

Market Opportunities

Increasing research on rare blood diseases and their treatments.

The increasing focus on rare blood diseases presents a significant growth opportunity for the global blood preparation market. Rare blood disorders, like paroxysmal nocturnal hemoglobinuria (PNH), sickle cell anemia, and hemophilia, are receiving heightened attention from pharmaceutical companies and research institutions. This is driven by advancements in genomics and biotechnology, which are enabling the development of targeted and more effective treatments.

• For instance, in December 2023, Novartis received FDA approval for Fabhalta® (iptacopan), marking a significant advancement in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare chronic blood disorder. Fabhalta is the first oral monotherapy approved for adults with PNH, offering an alternative to existing intravenous therapies.

The pursuit of innovative therapies for such conditions is expected to expand treatment options and foster investment in blood preparation technologies.

Regional Insights

North America's blood preparation market is expanding due to high healthcare expenditure, advanced medical infrastructure, and increasing awareness of blood-related disorders. The region sees strong demand for anticoagulants and plasma-derived therapies owing to the growing geriatric population and high prevalence of cardiovascular conditions. Robust support for research and development, along with the widespread adoption of cutting-edge technologies in blood processing and safety, further drives market growth. Additionally, well-established networks of blood banks and streamlined regulatory processes encourage innovation and consistent product availability across this region.

U.S. Blood Preparation Market Trends

• The United States market is driven by advanced healthcare infrastructure and rising cases of chronic diseases. For instance, the CDC reports over 900,000 people suffer from venous thromboembolism annually. Additionally, companies like Baxter and CSL Behring are investing heavily in plasma-derived therapies. The adoption of AI-based blood screening tools also enhances efficiency in hospitals and blood banks, supporting market growth.
• Canada’s blood preparation industry is expanding due to increased government support and public health awareness. Canadian Blood Services has launched national donor campaigns to address plasma shortages. Rising surgeries and transfusions in aging populations further drive demand. Moreover, Health Canada’s regulations are encouraging safe and standardized practices. Partnerships with biotech firms, such as Octapharma’s plasma collection centers, highlight efforts to strengthen domestic plasma supply chains.

Asia Pacific Blood Preparation Market Trends

Asia Pacific exhibits rapid growth in the market for blood preparation owing to improving healthcare infrastructure and rising awareness of blood disorders. Increasing investments in public health, coupled with a growing population base requiring transfusions for surgeries and trauma care, drive demand. The region is witnessing expanding access to modern blood processing technologies and anticoagulant therapies. A surge in diagnostic centers, blood banks, and healthcare reforms aimed at improving access to safe transfusions are enhancing market penetration. Additionally, increasing research collaborations support innovation in blood-based therapeutics and diagnostics.

• Japan’s blood preparation market is driven by its aging population and high demand for blood products like immunoglobulins and albumin. Advanced healthcare infrastructure supports the widespread use of recombinant therapies. For instance, Japan’s Red Cross Society actively promotes blood donation and maintains stringent safety standards. Moreover, collaborations like CSL Behring’s plasma collection initiatives in Japan are enhancing the supply of high-quality blood components.
• India’s blood preparation market is expanding due to growing healthcare access and increasing trauma and surgical cases. Rising awareness campaigns, like those led by the National Blood Transfusion Council, promote voluntary blood donation. Companies such as Reliance Life Sciences are investing in plasma fractionation facilities. However, regional disparities in blood storage and testing infrastructure present challenges, highlighting the need for modernization and equitable distribution across rural and urban areas.

Europe Blood Preparation Market Trends

Europe's blood preparation industry is bolstered by comprehensive healthcare systems, surging prevalence of chronic diseases, and consistent public health investments. The region emphasizes stringent quality standards and patient safety, fostering the adoption of advanced blood purification and pathogen-reduction technologies. Rising surgical volumes and aging demographics significantly contribute to the growing demand for blood components. Moreover, government-backed initiatives promoting voluntary blood donation and continuous innovation in biologics and anticoagulant therapies further enhance market prospects. The integration of digital health tools is also improving inventory management and transfusion accuracy across healthcare facilities.

• Germany's blood preparation market is driven by a robust healthcare infrastructure and high surgical volumes. The country has led the adoption of advanced anticoagulants like rivaroxaban. Organizations like the German Red Cross play a key role in blood collection. Increasing use of recombinant blood products and strong regulatory frameworks for blood safety also support market growth, especially in treating hemophilia and chronic cardiovascular conditions.
• The UK blood preparation market benefits from NHS-driven initiatives and advanced transfusion services. A growing elderly population has increased the demand for blood products in oncology and cardiac care. The NHS Blood and Transplant (NHSBT) service ensures efficient blood component delivery. Additionally, the rise in anticoagulant prescriptions, such as apixaban, and innovations in pathogen reduction technologies are enhancing market prospects across the country's public and private healthcare sectors.

Product Type Insights

Whole blood remains a dominant product segment in the market due to its critical role in emergency transfusions and trauma care. It is extensively used in surgeries, severe blood loss cases, and major trauma, where rapid volume replacement is essential. Despite advancements in blood components, whole blood’s comprehensive composition of red cells, plasma, and platelets makes it indispensable in critical care settings. Moreover, its relatively straightforward collection and storage processes contribute to its widespread use. Growing demand in developing regions with increasing trauma incidents and surgical procedures further reinforces whole blood’s dominance in the market.

Antithrombotic & Anticoagulant Type Insights

Anticoagulants hold a leading position in the market owing to their vital role in preventing and treating thromboembolic disorders. With the rising prevalence of cardiovascular diseases, deep vein thrombosis, and pulmonary embolism globally, anticoagulants like heparins and direct oral anticoagulants are extensively prescribed. Their ability to reduce blood clot formation improves patient outcomes in surgeries and chronic disease management. Technological advancements producing safer and more effective anticoagulants, alongside growing awareness of blood clot risks, further drive market growth. Additionally, the expanding elderly population with higher susceptibility to clotting disorders sustains demand for this segment.

Application Insights

Thrombocytosis represents a dominant application segment in the market due to the increasing diagnosis of platelet disorders linked with cardiovascular and myeloproliferative diseases. Elevated platelet counts heighten risks of clot formation, stroke, and heart attack, necessitating specialized blood products and antithrombotic treatments. Enhanced diagnostic capabilities and growing awareness enable early detection and treatment, expanding market demand. Treatment regimens often include platelet concentrates and anticoagulants, driving product consumption. Furthermore, the rise in chronic diseases and cancer treatments that induce thrombocytosis also supports the steady growth of this application segment globally.

End-user Insights

Hospitals constitute the largest end-user segment in the market due to their critical role in managing emergencies, surgeries, and chronic disease treatments. They maintain large inventories of blood and blood products to support transfusions, trauma care, and complex procedures like organ transplants. Hospitals’ adoption of advanced blood preparation technologies and compliance with stringent safety regulations further enhance demand. The increasing number of hospital admissions, rising surgical interventions, and expanding healthcare infrastructure worldwide, particularly in emerging economies, drive the segment’s growth. Additionally, hospitals’ strategic partnerships with blood banks ensure the timely availability of essential blood products.

Company Market Share

Companies in the blood preparation market are focusing on expanding their product portfolios through the development of advanced anticoagulants and blood component separators. Strategic collaborations with healthcare providers, investments in R&D for pathogen-free and recombinant products, and geographical expansion into emerging markets are key growth strategies. Additionally, firms are enhancing their manufacturing capabilities and leveraging digital tools to improve supply chain efficiency and ensure the safe, timely delivery of blood products.

Pfizer Inc: Pfizer Inc., founded in 1849 and headquartered in New York, USA, is a leading global biopharmaceutical company. It plays a significant role in the market through its portfolio of anticoagulant and antiplatelet therapies. With a strong focus on cardiovascular and hematological conditions, Pfizer has developed widely used drugs like Eliquis (apixaban) for blood clot prevention. The company invests heavily in R&D and collaborates with global healthcare organizations to advance treatment accessibility and innovation in blood disorder therapies worldwide.

• In October 2024, the U.S. FDA approved Pfizer’s HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescents (12 years and older) with hemophilia A or B without inhibitors. This once-weekly subcutaneous treatment is the first anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for these conditions and is administered via a pre-filled pen or syringe, offering a convenient alternative to traditional intravenous infusions.

Recent Developments

• May 2025- Scientists at the Indian Institute of Information Technology, Allahabad (IIIT-A) have developed an affordable device capable of rapidly separating plasma from blood and purifying water. Utilizing hydrodynamic micro-channels, the device processes blood components such as RBCs, WBCs, platelets, and plasma within minutes. The device also filters water contaminants, including bacteria and particles as small as 2 nanometers, and doesn't require replaceable filters.
• January 2025- The Allen Institute has introduced CryoSCAPE, a technology designed to stabilize blood samples for single-cell RNA sequencing. This method preserves the natural state of cells, allowing for accurate gene expression analysis even hours after blood collection. CryoSCAPE enables the processing of hundreds of blood samples simultaneously, broadening the reach of immunology studies and facilitating research in various applications.